TellBio Inc. is a biotechnology company focused on transforming cancer detection and treatment through its proprietary TellDx CTC System, which isolates circulating tumor cells (CTCs) from patient liquid biopsies. This innovative platform is designed to enhance the early detection and monitoring of cancer progression, addressing significant unmet medical needs in the field. The TellDx technology is based on extensive academic and clinical research, exclusively licensed from Massachusetts General Hospital, and is currently utilized as a research tool in various centers of excellence globally. By isolating viable CTCs, the TellDx platform provides a unique opportunity to analyze cancer biology and potentially guide therapeutic decisions, particularly in cases of advanced metastatic disease.

Recent studies utilizing the TellDx technology have demonstrated its potential in predicting patient outcomes and responses to therapies in various cancer types, including prostate and breast cancer. For instance, analyses of CTCs have revealed critical epigenetic changes that can inform treatment strategies, such as identifying resistance mechanisms to endocrine therapies in hormone receptor-positive breast cancer. The ability to isolate and study CTCs not only aids in understanding cancer progression but also positions TellBio's technology as a promising tool for developing targeted therapies and improving patient care in oncology.

United States

TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform,

TellBio

Company Details